199 related articles for article (PubMed ID: 11603386)
41. Efficient evaluation of humoral immune responses by the use of serum pools.
Sternbæk L; Draborg AH; Nielsen CT; Jacobsen S; Iversen LV; Troelsen L; Theander E; Houen G
J Immunol Methods; 2017 Apr; 443():1-8. PubMed ID: 28130033
[TBL] [Abstract][Full Text] [Related]
42. Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases.
Chrostek L; Cylwik B; Gindzienska-Sieskiewicz E; Gruszewska E; Szmitkowski M; Sierakowski S
Rheumatol Int; 2014 Mar; 34(3):393-9. PubMed ID: 24346772
[TBL] [Abstract][Full Text] [Related]
43. Abnormal structures in circulating lymphocytes from patients with systemic lupus erythematosus and related diseases.
Grrimley PM; Decker JL; Michelitch HJ; Frantz MM
Arthritis Rheum; 1973; 16(3):313-23. PubMed ID: 4708012
[No Abstract] [Full Text] [Related]
44. [Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].
Yu JF; Jin YB; He J; An Y; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):910-914. PubMed ID: 29045979
[TBL] [Abstract][Full Text] [Related]
45. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
[TBL] [Abstract][Full Text] [Related]
46. [Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
Sosnovskaya AV; Fomin VV; Popova EN; Lebedeva MV; Moiseev SV; Svistunov AA; Mukhin NA
Ter Arkh; 2015; 87(3):42-47. PubMed ID: 26027239
[TBL] [Abstract][Full Text] [Related]
47. Serum CCL23 levels are increased in patients with systemic sclerosis.
Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Asano Y; Kadono T; Sato S
Arch Dermatol Res; 2011 Jan; 303(1):29-34. PubMed ID: 20824279
[TBL] [Abstract][Full Text] [Related]
48. Is there circadian variation of plasma endothelin (ET-1) in patients with systemic scleroderma (SSc)?
Maeda M; Kachi H; Takagi H; Kitajima Y
J Dermatol Sci; 1997 Nov; 16(1):38-44. PubMed ID: 9438906
[TBL] [Abstract][Full Text] [Related]
49. Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population-Based Study.
McCormick N; Marra CA; Sadatsafavi M; Kopec JA; Aviña-Zubieta JA
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):142-154. PubMed ID: 29648677
[TBL] [Abstract][Full Text] [Related]
50. [Diagnosis of collagen diseases. Clinical and immunological guiding symptoms].
Berg PA
Internist (Berl); 1984 Jan; 25(1):37-50. PubMed ID: 6370893
[No Abstract] [Full Text] [Related]
51. Increased frequency of class I and II anti-human leukocyte antigen antibodies in systemic lupus erythematosus and scleroderma and associated factors: a comparative study.
Tozkir H; Pamuk ON; Duymaz J; Gurkan H; Yazar M; Sari G; Tanrikulu H; Pamuk GE
Int J Rheum Dis; 2016 Dec; 19(12):1304-1309. PubMed ID: 25292400
[TBL] [Abstract][Full Text] [Related]
52. [Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis].
Kondo A; Oketani N; Maruyama M; Taguchi Y; Yamaguchi Y; Miyao H; Mashima I; Oono M; Wada K; Tsuchiya T; Takahashi H; Abe S
Kekkaku; 1998 Oct; 73(10):585-90. PubMed ID: 9844346
[TBL] [Abstract][Full Text] [Related]
53. Identification of a Novel Serum Proteomic Signature for Primary Sjögren's Syndrome.
Padern G; Duflos C; Ferreira R; Assou S; Guilpain P; Maria ATJ; Goulabchand R; Galea P; Jurtela M; Jorgensen C; Pers YM
Front Immunol; 2021; 12():631539. PubMed ID: 33708222
[TBL] [Abstract][Full Text] [Related]
54. Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases.
Luft LM; Barr SG; Martin LO; Chan EK; Fritzler MJ
J Rheumatol; 2003 Dec; 30(12):2613-9. PubMed ID: 14719202
[TBL] [Abstract][Full Text] [Related]
55. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
56. A hypersensitive biotin-avidin-TRFIA for quantitative detection of ANA-Ig(GAM) and its clinical application.
Liu J; Ye Y; Hu Z; Zou Y; Chen G; Yu L
J Immunoassay Immunochem; 2013; 34(2):197-207. PubMed ID: 23537303
[TBL] [Abstract][Full Text] [Related]
57. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.
Park EH; Strand V; Oh YJ; Song YW; Lee EB
Arthritis Res Ther; 2019 Feb; 21(1):61. PubMed ID: 30770765
[TBL] [Abstract][Full Text] [Related]
58. Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis.
Ateş A; Kinikli G; Turgay M; Duman M
Scand J Immunol; 2004 Mar; 59(3):315-20. PubMed ID: 15030584
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis.
Jeong S; Yang D; Lee W; Kim GT; Kim HS; Ahn HS; Kim HJ
Semin Arthritis Rheum; 2018 Oct; 48(2):334-342. PubMed ID: 29609799
[TBL] [Abstract][Full Text] [Related]
60. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
